Similar articles for PMID: 21687025

Year	Number of Results
1988	2
1989	1
1991	1
1992	1
1993	6
1994	2
1995	5
1996	2
1997	7
1998	2
1999	3
2000	1
2001	5
2002	1
2003	6
2004	3
2005	3
2006	2
2007	8
2008	6
2009	7
2010	3
2011	2
2012	2
2013	2
2015	3
2016	3
2017	4
2018	4
2019	2
2020	1
2021	1
2024	0

1

Sotalol induced QT prolongation and torsades de pointes.

Chong DW, Ankolekar SJ, McDonald J. Chong DW, et al. BMJ Case Rep. 2009;2009:bcr01.2009.1426. doi: 10.1136/bcr.01.2009.1426. Epub 2009 Apr 3. BMJ Case Rep. 2009. PMID: 21687025 Free PMC article. No abstract available.

2

Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.

Couderc JP, Kaab S, Hinterseer M, McNitt S, Xia X, Fossa A, Beckmann BM, Polonsky S, Zareba W. Couderc JP, et al. J Clin Pharmacol. 2009 Jan;49(1):6-16. doi: 10.1177/0091270008325927. Epub 2008 Oct 28. J Clin Pharmacol. 2009. PMID: 18957528 Clinical Trial.

3

Analyses of dynamic beat-to-beat QT-TQ interval (ECG restitution) changes in humans under normal sinus rhythm and prior to an event of torsades de pointes during QT prolongation caused by sotalol.

Fossa AA, Wisialowski T, Crimin K, Wolfgang E, Couderc JP, Hinterseer M, Kaab S, Zareba W, Badilini F, Sarapa N. Fossa AA, et al. Ann Noninvasive Electrocardiol. 2007 Oct;12(4):338-48. doi: 10.1111/j.1542-474X.2007.00183.x. Ann Noninvasive Electrocardiol. 2007. PMID: 17970959 Free PMC article.

4

Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.

Kühlkamp V, Mermi J, Mewis C, Seipel L. Kühlkamp V, et al. J Cardiovasc Pharmacol. 1997 Mar;29(3):373-81. doi: 10.1097/00005344-199703000-00011. J Cardiovasc Pharmacol. 1997. PMID: 9125676

5

Experimental models of torsades de pointes.

Weissenburger J, Davy JM, Chézalviel F. Weissenburger J, et al. Fundam Clin Pharmacol. 1993;7(1):29-38. doi: 10.1111/j.1472-8206.1993.tb00215.x. Fundam Clin Pharmacol. 1993. PMID: 8458600 Review.

6

Gastroenteritis with severe consequences: a case of sotalol-induced torsades de pointes.

Michiels V, Miljoen H, Vrints C. Michiels V, et al. Acta Cardiol. 2009 Dec;64(6):839-42. doi: 10.2143/AC.64.6.2044756. Acta Cardiol. 2009. PMID: 20128168

7

Torsades de pointes with a severely prolonged QT interval induced by an initial low dose sotalol intake.

Yalta K, Turgut O, Yilmaz A, Yilmaz MB, Kendirlioglu O, Karadas F. Yalta K, et al. Int J Cardiol. 2007 Apr 4;116(3):e95-7. doi: 10.1016/j.ijcard.2006.08.091. Epub 2006 Nov 27. Int J Cardiol. 2007. PMID: 17126428

8

The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.

Tisdale JE, Rasty S, Padhi ID, Sharma ND, Rosman H. Tisdale JE, et al. J Clin Pharmacol. 2001 Dec;41(12):1310-8. doi: 10.1177/00912700122012896. J Clin Pharmacol. 2001. PMID: 11762558

9

K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.

Hasumi H, Matsuda R, Shimamoto K, Hata Y, Kaneko N. Hasumi H, et al. Eur J Pharmacol. 2007 Jan 19;555(1):54-60. doi: 10.1016/j.ejphar.2006.10.005. Epub 2006 Oct 17. Eur J Pharmacol. 2007. PMID: 17112502

10

Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.

Eckardt L, Breithardt G, Haverkamp W. Eckardt L, et al. J Pharmacol Exp Ther. 2002 Jan;300(1):64-71. doi: 10.1124/jpet.300.1.64. J Pharmacol Exp Ther. 2002. PMID: 11752098

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

90 results

Results by year